Galecto, Inc. (GLTO)
- Previous Close
0.6299 - Open
0.6200 - Bid 0.5817 x 100
- Ask 0.6546 x 100
- Day's Range
0.6131 - 0.6275 - 52 Week Range
0.5000 - 3.7000 - Volume
53,729 - Avg. Volume
192,975 - Market Cap (intraday)
16.897M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1300 - Earnings Date Jul 29, 2024 - Aug 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
galecto.comRecent News: GLTO
Performance Overview: GLTO
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLTO
Valuation Measures
Market Cap
17.08M
Enterprise Value
-9.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.95%
Return on Equity (ttm)
-78.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.83M
Diluted EPS (ttm)
-1.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
27.17M
Total Debt/Equity (mrq)
0.55%
Levered Free Cash Flow (ttm)
-20.74M